|
Uniparental disomy, paternal, chromosome 14
|
0.310 |
ChromosomalRearrangement
|
disease |
ORPHANET |
Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes.
|
18176563 |
2008 |
|
Uniparental disomy, paternal, chromosome 14
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Although recent studies in patients with paternal uniparental disomy 14 [upd(14)pat] and other conditions affecting the chromosome 14q32.2 imprinted region have successfully identified underlying epigenetic factors involved in the development of upd(14)pat phenotype, several matters, including regulatory mechanism(s) for RTL1 expression, imprinting status of DIO3 and placental histological characteristics, remain to be elucidated.
|
22917972 |
2012 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The safety and immunologic response of a plasmid encoding the MART-1 melanocyte differentiation antigen was evaluated in 12 patients with resected melanoma at risk for relapse.
|
16000957 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Replication-deficient recombinant adenovirus (Ad) encoding human gp100 or MART-1 melanoma Ag was used to transduce human dendritic cells (DC) ex vivo as a model system for cancer vaccine therapy.
|
10706736 |
2000 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
|
12244204 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To establish whether or not the use of tyrosinase-specific or melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction (RT--PCR) of peripheral blood cells detects preclinical disease progression in patients with malignant melanoma.
|
11251559 |
2001 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we examined whether cis-diaminedichloroplatinum (II) cisplatin (CDDP) sensitizes MART-1/HLA A2.1(+) melanoma and melanoma variant tumor cells to non-MHC-restricted, Fas ligand (FasL)-mediated killing by CTL.
|
11207317 |
2001 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To establish a mouse model for the use of these 'self' antigens as targets for anti-tumor immune responses, we have employed the mouse homologues of the human melanoma antigens Tyrosinase, Tyrosinase Related Protein-1 (TRP-1), gp100, and MART-1.
|
9692858 |
1998 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, not all IHC-positive cells in SLN are metastatic melanoma, as evidenced by the presence of MART-1 positive cells in SLN from breast cancer patients with no history of melanoma (so-called 'false-positive' cells).
|
18697715 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
|
30520800 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MART-1/Melan-A human melanoma tumor antigen can be recognized by T lymphocytes and appears to be involved in tumor regression.
|
9218710 |
1997 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MAb A103 allows the detection of melanoma-associated Melan A/MART-1 protein expression in routine archival tissue and thus enables the profiling of melanomas suited for immunotherapy approaches involving Melan A/MART-1 derived epitopes.
|
9764809 |
1998 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor infiltrating lymphocytes from a patient with melanoma were isolated, expanded in vitro in the presence of interleukin-2, and tested for cytotoxicity against HLA-A2 positive, MART-1 positive autologous tumor cells, an HLA-A2-positive, MART-1 positive melanoma cell line (Mel-501), and HLA-A2-negative melanoma cells.
|
10687135 |
2000 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.
|
12819038 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A retrospective cohort study evaluated 123 melanomas excised using MMS with MART-1 immunostain.
|
30199430 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA.
|
15746042 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, 23 of 29 CD8+ clones lysed T2 cells pulsed with the MART-1(27-35) peptide and 15 of 29 lysed the HLA-A2+ melanoma line 888.
|
10384155 |
1999 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MART-1 epitope was detected by IHC in 23/24 primary melanomas (96%), 9/9 metastatic melanomas (100%) and 5/6 nevi (83%).
|
18204435 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-12-stimulated iNKT cells strongly enhanced the MART-1 (melanoma Ag recognized by T cell 1)-specific CD8(+) CTL response, which was dependent on iNKT cell-derived IFN-gamma.
|
18684935 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In view of this, we performed an extensive cytogenetic analysis of hTERT-transduced MART-1 (melanoma antigen recognized by T cell 1)-and human papillomavirus type 16 (HPV16) E7-specific human CD8+ cytotoxic T lymphocytes (CTLs), reactive against melanoma and cervical carcinoma, respectively.
|
16002425 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Shave biopsy and immunohistochemical studies revealed that the tumor was composed of malignant melanoma (MM) (highlighted by S100 and MART-1) intermixed with squamous cell carcinoma (SCC) (highlighted by cytokeratin and p63), and a diagnosis of combined MM-SCC was rendered.
|
31361351 |
2020 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similarly, impressive clinical responses were seen in melanoma and synovial cell carcinoma with TCR-modified T cells redirected against the melanocyte lineage antigen MART-1 and the testis-cancer antigen NY-ESO-1.
|
23804078 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By T cell receptor clonotypic mapping and staining with tetrameric HLA-peptide complexes, we demonstrate the presence of melanocyte differentiation antigen MART-1 specific T cells in the areas of destruction of both neoplastic and normal melanocytic cells in a case of a primary melanoma and its associated hypopigmentation.
|
11918704 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with melanoma who enrolled in the F5-MART-1 clinical trial (NCT00910650) received infusions of MART-1 T-cell receptors transgenic T cells with MART-1 peptide-pulsed dendritic cell vaccination.
|
29470191 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, subcutaneous immunization of C57BL/6J mice with DCs ex vivo transfected with an electrostatic complex of AuNPs-SL & melanoma antigen (MART1) encoded DNA vaccine (p-CMV-MART1) induced a long lasting (100 days) anti-tumor immune response in immunized mice upon subsequent challenge with a lethal dose of melanoma.
|
30964937 |
2019 |